Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 21-Mar-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg, and 200 mg.
Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 21-Mar-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg, and 200 mg.